Barclays has downgraded Exact Sciences Corp (EXAS) to Equal-Weight from Overweight as of November 20, 2025. The stock is currently priced at $101.00.
This move underscores a shift in sentiment towards the company's outlook, possibly reflecting concerns about competitive pressures and market conditions that could affect performance. Exact Sciences, a biotechnology firm based in Madison, Wisconsin, specializes in cancer screening and diagnostics, employing approximately 6,900 full-time staff. Its flagship product, the Cologuard test, is a non-invasive screening tool for colorectal cancer.
The company's market capitalization stands at $12.7 billion, with a trailing twelve months EPS of -5.42. Upcoming earnings are scheduled for August 4, 2026, with an estimated EPS of $0.09 and revenue of $935.5 million. Recent performance has been mixed, highlighted by a Q3 2025 EPS of -0.10, which was a 40.1% miss against expectations.
Analyst ratings and price targets serve as professional opinions based on extensive research and financial modeling. While they can provide valuable insights, they are grounded in assumptions that may not always materialize. As such, investors should consider a range of factors, including company fundamentals and market dynamics, when evaluating their positions. Analyst opinions can evolve, and differing perspectives on the same company are common.